Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIBP 5371 in Healthy Volunteers
NCT02256709Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2004
- Primary completion
- Aug 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BIBP-5371 in migraine (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with changes in vital signs up to 8 days, Number of patients with changes in electrocardiogram (ECG) up to 8 days and 3 more. Started Apr 2004; status: completed.
02
Drugs
BIBP-5371
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02256709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256709.